Quantcast

Latest Interferon Stories

2014-03-25 23:30:00

Markets Research Reports.biz added deep and professional market research reports on "Global Cancer Vaccines Competitor Analysis And Market Research" Market Analysis and Overview. Albany, NY (PRWEB) March 25, 2014 The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to...

2014-03-25 23:29:51

Markets Research Reports.biz added deep and professinal market research reports on "Global Endoscopy Market Report 2014" Market Analysis and Overview. Albany, NY (PRWEB) March 25, 2014 Endoscopy is a minimally invasive diagnostic medical procedure in which a tube like instrument, known as endoscope, is used to look inside the body and examine organs. There are many different types of endoscopes available in the market; some are flexible and rigid while few are in a form of...

2014-03-24 08:28:25

CORK, Ireland, March 24, 2014 /PRNewswire/ -- New data from the clinical development program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease will be presented at The International Liver Congress(TM) of the European Association for the study of the Liver (EASL). The International Liver Congress(TM) 2014 will take place from April 9-13 in London....

2014-03-24 04:22:12

NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12. In presentations at the ILC, investigators will share detailed data results of four studies from AbbVie's phase III clinical trial program, the...

2014-03-10 08:28:58

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to...

2014-03-03 16:25:42

-- SVR(12) rates of 99 percent with and without ribavirin were achieved in genotype 1b patients new to treatment BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12...

2014-02-02 23:02:36

ResearchMoz include new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Industry Size, Shares, Growth, Trends and Forecast 2019" to its huge collection of research reports. Browse reports in Therapeutic Area - http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) February 02, 2014 “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to...

2014-01-31 08:25:10

- Ninety-nine percent SVR(12) rates with and without ribavirin in certain patient types NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. These results described below...

2014-01-29 23:32:21

Health and Harmony LLC now offers a natural way to increase the immune system, gain added protection against the flu, and offset the unwanted side effects that so many prescription drugs can cause with a natural, nonaddictive immune booster created by world-renowned immunologist Dr. Yasuhiko Kojima. Peoria, IL (PRWEB) January 29, 2014 Health and Harmony LLC now offers a natural way to increase the immune system, gain added protection against the flu, and offset the unwanted side effects...

2014-01-16 10:01:37

Study shows safe and simpler treatment for potentially deadly, liver-damaging disease Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere. In a study to be reported in the Jan. 16 issue of the New England Journal of Medicine, researchers say combination treatments involving a pair of experimental, oral antiviral...


Latest Interferon Reference Libraries

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (1 articles) »
Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related